**TELEMETERED LEFT-VENTRICULAR PRESSURE IN YUCATAN MINI-PIGS: CHRONIC EVALUATION IN A NOVEL GENETIC MODEL OF NON-OBSTRUCTED HYPERTROPHIC CARDIOMYOPATHY**

Beth Geist¹, Bradley L. Youngblood², Yukie Ueyama³, Amanda LaRose¹, Robert Hamlin¹, Marc J. Evanichk², Carlos del Rio¹,²

¹QTest Labs, Columbus, OH; ²MyoKardia, San Francisco, CA

**INTRODUCTION & METHODS**

Mini-pigs are a popular model for safety pharmacology pre-clinical evaluations, and recent advances permit their genetic manipulation in order to study states of cardiovascular dysfunction. However, the feasibility of telemetered left-ventricular pressure-assessments, particularly in the setting of induced cardiomyopathy remains to be explored. For these in vivo experiments, juvenile Yucatan mini-pigs with a heterozygous MYH7 R403Q mutation (n = 4) and wild-type (WT, n = 3) herd-mates were instrumented for left-ventricular pressure (LVP) and ECG telemetry via a left-lateral thoracotomy (emka easyTEL+ EPTA).

**RESULTS**

Following recovery from surgical instrumentation, all pigs had waveforms suitable for analysis. Healthy WT pigs had LVP parameters within physiologic ranges (HR: 96±6 bpm, EDP: 20±0.4 mmHg, ESP: 108±6 mmHg, dP/dt max: 1636±56 mmHg/s, dP/dt min: -1446±49 mmHg/s, tau: 23±1 msec). Meanwhile, age-matched mutant pigs with hypertrophic cardiomyopathy (HCM, n = 4) exhibited the anticipated LVP alterations, including elevated filling pressures (EDP: 36±5 mmHg) and impaired indices of relaxation (dP/dt min: -1112±57 mmHg/s). At approximately 6 months post-implantation, telemetry signals remained adequate to permit phenotype differentiation (e.g., EDP: 13±2 mmHg in WT, 35±2.4 mmHg in HCM pigs). At this time, left-ventricular telemetered signals were sensitive to the effects of acute metoprolol administration (2 mg/kg PO, MET), showing, for instance, reductions in dP/dt min (-7±2%) and HR (-5±1%).

**CONCLUSION**

Taken together, these results indicate the utility and durability of telemetered left-ventricular pressure in the mini-pig, in both health and in the presence of a novel phenotype of cardiac dysfunction.

QTest Labs is a CRO that specializes in cardiovascular safety, complete risk assessment, and the ex/in vivo evaluation of physiology, electrophysiology, toxicology, and pharmacology in both normal and diseased models. Via our patent-pending comprehensive paradigm and the extensive expertise of our scientists, QTest Labs can provide a clear mechanistic understanding of your test article and/or device.

Beth Geist, DVM, DSP
bg2657@cumc.columbia.edu